Peijia Medical

Peijia Medical

An interventional medical products provider. Learn more

Launch date
Employees
Market cap
€197m
Enterprise valuation
€110m (Public information from Sep 2024)
Suzhou Shi Jiangsu (HQ)

Financials

Estimates*

Edit
Revenues, earnings & profits over time
CNY2020202120222023202420252026
Revenues38.7m137m251m441m634m836m1.0b
% growth107 %253 %84 %76 %44 %32 %25 %
EBITDA(373m)(547m)(360m)(325m)(170m)(77.6m)41.8m
% EBITDA margin(965 %)(401 %)(143 %)(74 %)(27 %)(9 %)4 %
Profit(2.1b)(574m)(408m)(393m)(194m)(103m)(45.5m)
% profit margin(5352 %)(421 %)(163 %)(89 %)(31 %)(12 %)(4 %)
EV / revenue325.4x36.4x16.5x9.0x2.3x2.1x1.8x
EV / EBITDA-33.7x-9.1x-11.5x-12.2x-8.6x-22.2x44.5x
R&D budget103m446m373m293m---
R&D % of revenue267 %327 %149 %67 %---
  • Edit
DateInvestorsAmountRound
-

N/A

-

N/A

Series A

N/A

Series B

$100m

Series C
*
N/A

$302m

IPO
N/A

$128m

Private Placement VC
Total Funding€207m

Recent News about Peijia Medical

Edit
More about Peijia Medicalinfo icon
Edit

Peijia Medical Limited, established in 2012 and headquartered in Suzhou, China, is a prominent player in the interventional procedural medical device market. The company focuses on developing and providing innovative medical devices aimed at treating structural heart diseases and neurovascular diseases. Peijia Medical serves healthcare providers and hospitals, primarily within the Chinese market, but aims to expand its reach globally. The business model revolves around the research, development, and commercialization of advanced medical devices, generating revenue through the sale of these products. The company is listed on the Main Board of the Hong Kong Stock Exchange, reflecting its growth and investor confidence.

Keywords: interventional, medical devices, structural heart, neurovascular, innovation, healthcare, China, hospitals, commercialization, Hong Kong Stock Exchange.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by Peijia Medical

Edit
JenaValve Technology
ACQUISITION by Edwards Lifesciences Jul 2024